Algeta schedules Fourth Quarter 2009 Presentation
(Thomson Reuters ONE) - Oslo, Norway, 12 February 2010 - Algeta ASA (OSE: ALGETA),the Norwegian cancertherapeutics company, will announce its fourth quarter 2009 results on Friday,19 February 2010. A presentation to investors, analysts and the press will takeplace in Oslo at 08:00 CET. Algeta's President and CEO Andrew Kay, CTO ThomasRamdahl and CFO ?stein Soug will present.An international conference call will take place at 14:30 CET (details below).Andrew Kay, Thomas Ramdahl and ?stein Soug will participate.The presentation will take place at 08:00 CET at:Hotel ContinentalStortingsgaten 24/260117 OsloNorway.Breakfast will be served from 07:45 CET.To participate in the conference call, please dial the appropriate number belowfive minutes prior to the call:800 80 119 (in Norway)+47 23 18 45 01 (from abroad).The results report and the presentation will be made available on www.algeta.com in the Investors section from 08:00 CET.To access the replay, please dial +47 23 18 45 02. Enter account no. 1428followed by #, then conference no. 428 followed by #. A replay version of theconference call will also be available at www.algeta.com. ###For further information, please contact Andrew Kay, CEO +47 23 00 67 42 / +47 484 01 360 (mob) ?stein Soug, CFO +47 23 00 79 84 / +47 906 56 525 (mob) post(at)algeta.com Dr Mark Swallow / David Dible / Helena +44 (0) 207 638 9571 Galilee mark.swallow(at)citigatedr.co.uk Citigate Dewe RogersonAbout AlgetaAlgeta is a focused oncology company developing novel targeted therapies forpatients with cancer based on its alpha-pharmaceutical platform.Algeta's lead product Alpharadin (based on radium-223) is a first-in-class,highly targeted alpha-pharmaceutical under clinical evaluation to improvesurvival in patients with bone metastases from advanced cancer. Its localizedaction helps preserve the surrounding healthy tissue thereby limitingside-effects.The development of bone metastases represents a serious development for cancerpatients as they are associated with a dramatic decline in patient health andquality of life, ultimately leading to death. Bone metastases represent a majorunmet medical need, occurring in up to 90% of certain late-stage cancers, e.g.prostate, breast and lung.Alpharadin is partnered with Bayer Schering Pharma AG, a major pharmaceuticalcompany, and is in a global phase III clinical trial (ALSYMPCA) to treat bonemetastases resulting from hormone-refractory (castration-resistant) prostatecancer. Alpharadin is also under investigation in phase II clinical trials as apotential new treatment for bone metastases in endocrine resistant breast cancerpatients.Algeta also aims to develop a future pipeline of tumor-targetingalpha-pharmaceutical candidates based on the alpha particle emitter thorium-227,through selective in-licensing and/or acquiring innovative technologies andtumor-targeting molecules.The Company is headquartered in Oslo, Norway, and was founded in 1997. Algetalisted on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).Alpharadin and Algeta are trademarks of Algeta ASA.Forward-looking StatementThis news release contains forward-looking statements and forecasts based onuncertainty, since they relate to events and depend on circumstances that willoccur in the future and which, by their nature, will have an impact on resultsof operations and the financial condition of Algeta. There are a number offactors that could cause actual results and developments to differ materiallyfrom those expressed or implied by these forward-looking statements. Thesesfactors include, among other things, risks associated with technologicaldevelopment, the risk that research & development will not yield new productsthat achieve commercial success, the impact of competition, the ability to closeviable and profitable business deals, the risk of non-approval of patents notyet granted and difficulties of obtaining relevant governmental approvals fornew products. ###This information is subject of the disclosure requirements acc. to §5-12 vphl(Norwegian Securities Trading Act)[HUG#1383942] Press release: http://hugin.info/134655/R/1383942/342807.pdf
Weitere Infos zu dieser Pressemeldung:Unternehmensinformation / Kurzprofil:Bereitgestellt von Benutzer: hugin
Datum: 12.02.2010 - 12:16 Uhr
Sprache: Deutsch
News-ID 12442
Anzahl Zeichen: 0
contact information:
Town:
Kategorie:
Diese Pressemitteilung wurde bisher
163 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"
Algeta schedules Fourth Quarter 2009 Presentation"
steht unter der journalistisch-redaktionellen Verantwortung von
Algeta ASA
(
Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum
Haftungsauschluß (gemäß
TMG - TeleMedianGesetz) und dem
Datenschutz (gemäß der
DSGVO).
Oslo, Norway, 11 December - Algeta ASA (OSE: ALGETA), the cancer
therapeutics company, announces that the first clinical center in the
US, the Tulane Cancer Center, New Orleans, has started randomizing
patients in the phase III clinical study of Alph ...
Oslo, Norway, 13 November 2009 - Algeta ASA (OSE: ALGETA), the cancer
therapeutics company, today announces its results for the third
quarter 2009. An international conference call will take place today
at 14:30 CET (details below).
Highlights of t ...
